Case Report

Functional Movement Disorder; Importance of Proper Diagnosis and Treatment: A Case Report

Abstract

 Background: Dystonia is a common movement disorder with a wide range of aetiologies. Delays in the identification and initiation of effective treatments should be minimized to improve patient pain and optimize outcomes. This case report aims to underscore the successful treatment of chronic dystonia with the use of mood-modifying serotonin and norepinephrine reuptake inhibitors (SNRI), and encourage clinicians to consider a diagnosis of functional (psychogenic) movement disorder in patients with dystonia that is refractory to usual treatment.

 

Case Report: This case report describes a 40-year-old woman who presented to a chronic pain clinic for pain related to cervical dystonia with associated head tremor. Her symptoms were refractory to nearly a decade of quarterly botulinum toxin injections. Based on careful evaluation of the patient’s history, a normal neurological examination, increased Generalized Anxiety Disorder Scale (GAD-7), Patient Health Questionnaire-9 (PHQ-9), and Injustice Experiences Questionnaire (IEQ) scores, and unsuccessful symptom management with botulinum toxin A, a diagnosis of functional movement disorder (FMD) was made. Low-dose Cymbalta was initiated. The patient achieved near complete symptom remission and resolution of her chronic pain within 2 months and achieved near complete resolution in 2 years.

 

Conclusion: A diagnosis of FMD should be considered in all patients with dystonia, but especially in patients who respond inadequately to botulinum toxin injections or other rehabilitation therapies. The treatment of comorbid psychiatric conditions can result in substantial benefits and remission from dystonia due to FMD.

1. Ford B, Geyer H, Bressman SB. Movement disorders. In: Brust JCM, editor. Current diagnosis and treatment neurology. 3rd ed. New York, NY: McGraw-Hill Education; 2019.

2. Tyslerowicz M, Kiedrzynska W, Adamkiewicz B, Jost WH, Slawek J. Cervical dystonia - improving the effectiveness of botulinum toxin therapy. Neurol Neurochir Pol. 2020;54(3):232-42. doi: 10.5603/PJNNS.a2020.0021. [PubMed: 32285434].

3. Grutz K, Klein C. Dystonia updates: Definition, nomenclature, clinical classification, and etiology. J Neural Transm (Vienna). 2021;128(4):395-404. doi: 10.1007/s00702-021-02314-2. [PubMed: 33604773]. [PubMed Central: PMC8099848].

4. Stein J, Chowdhury N. Spasticity and contractures. In: Mitra R, editor. Principles of rehabilitation medicine. New York, NY: McGraw-Hill Education; 2019.

5. Lidstone SC. Functional movement disorders. UpTodate [Online]. [cited 2023 Feb 22]; Available from: URL: https://www.uptodate.com/contents/functional-movement-disorders

6. Lidstone SC, Costa-Parke M, Robinson EJ, Ercoli T, Stone J. Functional movement disorder gender, age and phenotype study: A systematic review and individual patient meta-analysis of 4905 cases. J Neurol Neurosurg Psychiatry. 2022;93(6):609-16. doi: 10.1136/jnnp-2021-328462. [PubMed: 35217516].

7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5TM. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.

8. Tilton AH. Injectable neuromuscular blockade in the treatment of spasticity and movement disorders. J Child Neurol. 2003;18(Suppl 1):S50-66. doi: 10.1177/0883073803018001S0701. [PubMed: 13677571].
Files
IssueVol 9 No 4 (2023) QRcode
SectionCase Report
DOI https://doi.org/10.18502/jost.v9i4.13936
Keywords
Dystonia Torticollis Functional Movement Disorder Dystonic Disorders

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Shojaei H, Wilkins T. Functional Movement Disorder; Importance of Proper Diagnosis and Treatment: A Case Report. J Orthop Spine Trauma. 2023;9(4):185-8.